MLL3 and MLL4 sustain hematopoietic stem cell multipotency by opposing a B-cell default state

H Helen C. Wang (1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO) R Ran Chen (Shanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences) W Wei Yang R Rohini Muthukumar (1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO) T Tingting Hu R Riddhi M. Patel (1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO) E Emily B. Casey (1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO) E Elisabeth Denby (1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO) R Run Zhang (Department of Neuro‐Oncological Surgery Zhujiang Hospital Southern Medical University Guangzhou China) G Guojia Xie K Kai Ge G Grant A. Challen J Jeffrey J. Bednarski (1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO) J Jeffrey A. Magee (1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO)

Abstract

Abstract Hematopoietic stem cells (HSCs) and multipotent progenitors (MPPs) are sustained by networks of transcription factors and epigenetic regulators that prime lineage-specific programs yet maintain multipotency. Two epigenetic regulators, MLL3 and MLL4, play important but distinct roles in maintaining this balance. MLL3 promotes HSC differentiation, whereas MLL4 opposes differentiation. These activities are essential for both normal homeostasis and leukemia suppression, yet it is not clear how MLL3 and MLL4 regulate HSC and MPP gene expression to control HSC/MPP fate decisions. To resolve these mechanisms, we performed an extensive series of single-cell genomic studies after conditionally deleting Mll3, Mll4 or both genes together. Mll3 deletion had only limited effects on HSC/MPP enhancer networks at steady state, whereas Mll4 deletion led to precocious activation of myeloid enhancers. Surprisingly, compound Mll3/4 deletion eliminated all myeloid, erythroid, and megakaryocytic potential within the hematopoietic hierarchy and caused all progenitors to rapidly default to a B-cell–like identity. These changes were accompanied by widespread inactivation of HSC/MPP enhancers and superenhancers and ectopic activation of B-cell superenhancers. Disabling MLL3/4 histone methyltransferase activity did not recapitulate the pervasive changes in cell identity that were observed when MLL3 and MLL4 were fully inactivated, indicating that MLL3 and MLL4 activate HSC/MPP enhancers independently from their enzymatic activities. Our findings show that HSC/MPP multipotency requires sustained tension between MLL3/4-dependent enhancers that maintain myeloid, erythroid, and megakaryocyte potential and MLL3/4-independent enhancers that prime B-cell identity. MLL3 and MLL4 therefore serve as critical linchpins of multilineage hematopoiesis.

Article Details

Journal Blood
Volume / Issue Vol. 148, Issue 5
Published July 30, 2026
Pages 560-573
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (14)

H

Helen C. Wang

1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO

R

Ran Chen

Shanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences

W

Wei Yang

R

Rohini Muthukumar

1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO

T

Tingting Hu

R

Riddhi M. Patel

1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO

E

Emily B. Casey

1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO

E

Elisabeth Denby

1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO

R

Run Zhang

Department of Neuro‐Oncological Surgery Zhujiang Hospital Southern Medical University Guangzhou China

G

Guojia Xie

K

Kai Ge

G

Grant A. Challen

J

Jeffrey J. Bednarski

1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO

J

Jeffrey A. Magee

1Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO